MX2020004218A - Métodos y composiciones para inhibir las actividades biológicas de adam10. - Google Patents
Métodos y composiciones para inhibir las actividades biológicas de adam10.Info
- Publication number
- MX2020004218A MX2020004218A MX2020004218A MX2020004218A MX2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A
- Authority
- MX
- Mexico
- Prior art keywords
- adam10
- biological activities
- methods
- peptides
- inhibiting
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000036664 ADAM10 Human genes 0.000 abstract 5
- 108091007504 ADAM10 Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566580P | 2017-10-02 | 2017-10-02 | |
| US201762589842P | 2017-11-22 | 2017-11-22 | |
| PCT/US2018/053938 WO2019070685A1 (en) | 2017-10-02 | 2018-10-02 | METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004218A true MX2020004218A (es) | 2020-11-11 |
Family
ID=65995419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004218A MX2020004218A (es) | 2017-10-02 | 2018-10-02 | Métodos y composiciones para inhibir las actividades biológicas de adam10. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190345473A1 (enExample) |
| EP (1) | EP3691671A4 (enExample) |
| JP (2) | JP7448219B2 (enExample) |
| AU (1) | AU2018345601B2 (enExample) |
| CA (1) | CA3077694A1 (enExample) |
| IL (1) | IL273725A (enExample) |
| MX (1) | MX2020004218A (enExample) |
| WO (1) | WO2019070685A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247232B2 (en) | 2018-01-31 | 2025-03-11 | Verra Therapeutics, Inc. | Methods and compositions for inhibiting ADAM 9 biological activities |
| WO2020227714A1 (en) * | 2019-05-09 | 2020-11-12 | Verra Therapeutics, Llc | Methods and compositions for inhibiting adam8 biological activities |
| US20250177333A1 (en) * | 2022-03-08 | 2025-06-05 | Nova Southeastern University | Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270625A1 (en) | 2002-09-11 | 2004-04-30 | Justus-Liebig-Universität Giessen | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| CA2525574C (en) * | 2003-05-15 | 2015-06-30 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| KR101317358B1 (ko) | 2005-02-02 | 2013-10-15 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | Ａｄａｍ-9 조절자 |
| CA2604883A1 (en) | 2005-04-07 | 2006-10-19 | Albert Lai | Adam10 in cancer diagnosis, detection and treatment |
| US7638301B2 (en) * | 2006-08-28 | 2009-12-29 | Biozyme, Inc. | Prodomain modulators of ADAM 10 |
| US20090285840A1 (en) | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| US8079782B1 (en) | 2008-05-16 | 2011-12-20 | Hilfiker William K | Semi-extensible steel soil reinforcements for mechanically stabilized embankments |
| EP2637679A4 (en) * | 2010-11-09 | 2015-09-23 | Univ Chicago | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASES AND THERAPEUTICS |
| WO2012088105A2 (en) * | 2010-12-20 | 2012-06-28 | Biozyme Inc. | Methods and compositions for predicting disease status in cancer |
| WO2015117199A1 (en) | 2014-02-04 | 2015-08-13 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
-
2018
- 2018-10-02 JP JP2020520057A patent/JP7448219B2/ja active Active
- 2018-10-02 MX MX2020004218A patent/MX2020004218A/es unknown
- 2018-10-02 CA CA3077694A patent/CA3077694A1/en active Pending
- 2018-10-02 WO PCT/US2018/053938 patent/WO2019070685A1/en not_active Ceased
- 2018-10-02 AU AU2018345601A patent/AU2018345601B2/en active Active
- 2018-10-02 US US16/149,764 patent/US20190345473A1/en not_active Abandoned
- 2018-10-02 EP EP18865159.0A patent/EP3691671A4/en active Pending
-
2020
- 2020-03-31 IL IL273725A patent/IL273725A/en unknown
-
2022
- 2022-05-19 US US17/748,163 patent/US12297469B2/en active Active
-
2023
- 2023-11-01 JP JP2023187803A patent/JP2024012470A/ja active Pending
-
2025
- 2025-03-06 US US19/072,106 patent/US20250207119A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190345473A1 (en) | 2019-11-14 |
| US12297469B2 (en) | 2025-05-13 |
| US20230203468A1 (en) | 2023-06-29 |
| EP3691671A4 (en) | 2022-01-19 |
| JP2024012470A (ja) | 2024-01-30 |
| AU2018345601A1 (en) | 2020-05-21 |
| IL273725A (en) | 2020-05-31 |
| AU2018345601B2 (en) | 2025-05-15 |
| JP7448219B2 (ja) | 2024-03-12 |
| CA3077694A1 (en) | 2019-04-11 |
| WO2019070685A1 (en) | 2019-04-11 |
| US20250207119A1 (en) | 2025-06-26 |
| JP2021500321A (ja) | 2021-01-07 |
| EP3691671A1 (en) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4230644A3 (en) | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate | |
| MX2021006856A (es) | Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares. | |
| MX356129B (es) | Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| CO6561836A2 (es) | Polipeptidos agonistas que se enlazan a dr5 | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2020004218A (es) | Métodos y composiciones para inhibir las actividades biológicas de adam10. | |
| PH12013502609A1 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| AR072009A1 (es) | Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos | |
| WO2015183890A3 (en) | Methods and compositions for the treatment of metabolic disorders and diseases | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| GB201001602D0 (en) | Oligopeptidic compounds and uses therof | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| NZ774126A (en) | Spd-1 variant - fc fusion proteins | |
| CO2019013768A2 (es) | Compuestos de mic-1 y usos de estos | |
| MX2018015599A (es) | Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| PE20200894A1 (es) | Polipeptidos variantes del factor de crecimiento tipo insulina 1 | |
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| MX2015002994A (es) | Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. | |
| MX2020010807A (es) | Peptidos promotores del crecimiento y usos de los mismos. | |
| CU24746B1 (es) | Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular | |
| MX2017010259A (es) | Proteina resistente a herbicidas, gen codificante y uso de los mismos. |